Re: Zenith Updates

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

chicagoest

Rank: President [?]

Points: 1974 [?]

Votes: 20 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Updates

in response to

Re: Zenith Updates

BearDownAZ

posted on Feb 03, 2016 08:41AM

Dear BearDownAZ

Your explanation answers many of the questions I had and helps me to understand how RVX-208 and ZEN-3694 interact with other therapies. I'm beginning to grasp the extremely complex and onerous task at hand and the difficulty of pioneering this novel treatment.

Thank you so much for taking the time and sharing your valuable knowledge and expertise.

Sarah's comments regarding the Zenith reorganization suggest that an announcement on the trial commencement is imminent and priorities are in order.